Teriparatide
- Generic Name
- Teriparatide
- Brand Names
- Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva
- Drug Type
- Biotech
- CAS Number
- 52232-67-4
- Unique Ingredient Identifier
- 10T9CSU89I
Overview
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic therapy. Teriparatide is used in the treatment of osteoporosis in men and women.
Background
Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic therapy. Teriparatide is used in the treatment of osteoporosis in men and women.
Indication
Teriparatide is indicated:
Associated Conditions
- Osteoporosis
- Osteoporosis caused by Glucocorticoid Treatment
- Primary Osteoporosis
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.